Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ParkerVision, Inc.'s SEC filings document an OTCQB-traded Florida corporation focused on proprietary RF technologies, wireless applications, licensing, and patent enforcement. Its 8-K filings report operating results, legal and appellate developments involving patent claims, and material events that affect the company's capital structure and disclosure record.
The filing record also covers registered direct common stock offerings under a Form S-3 shelf registration statement, exchanges of convertible promissory notes for common stock, unregistered equity issuance disclosures, and executive compensation arrangements under the company's long-term incentive plan. These documents address governance approvals, share-based awards, financing terms, and risk references tied to patent proceedings and funding activity.
ParkerVision, Inc. asks shareholders to vote at the September 25, 2026 virtual annual meeting on electing two directors (Jeffrey L. Parker as Class I, Anthony B. Bowers as Class II) and ratifying Frazier & Deeter, LLC as independent registered public accounting firm for 2026. Directors are elected by plurality voting, and a majority of shares present and entitled to vote is required to ratify the auditor.
The company reports 148,226,874 shares of common stock outstanding as of July 29, 2026, with a quorum set at 74,113,438 shares. The board is majority independent and uses Nasdaq independence standards despite trading on OTCQB. Executive pay is heavily equity-based, with CEO 2025 total compensation of $2.10 million and CFO compensation of $443,462, influenced by option-modification accounting. In 2025 the compensation committee extended expiration dates on fully vested options, creating about $1.9 million in incremental share-based compensation, and in January 2026 granted sizable performance-based options tied to cumulative net cash from patent enforcement.
The proxy details related-party transactions, including a November 2025 registered direct sale of 4,761,905 shares at $0.21 per share to director Lewis Titterton for $1,000,000, director and law-firm note arrangements, and audit fees to Frazier & Deeter of $231,000 for 2025. Beneficial ownership shows directors and officers as a group holding 12.19% of outstanding shares, with a 9.99% holder, GEM Partners, LP. Shareholders are invited to submit proposals for the 2027 meeting under specified advance-notice and Rule 14a‑8 deadlines.
ParkerVision, Inc. filed a prospectus supplement covering the resale of up to 9,387,500 shares of common stock by selling shareholders, including 2,843,750 already issued shares, 6,343,750 shares issuable upon conversion of convertible notes at $0.16 per share, and 200,000 shares issuable upon option exercises. The company will not receive proceeds from resales, and would receive up to $42,620 only if the options are exercised for cash.
The attached quarterly report for the period ended June 30, 2026 shows total assets of $3.7 million against total liabilities of $48.3 million, resulting in a shareholders’ deficit of $44.6 million. Net income was $148,000 for the quarter and a net loss of $1.4 million for the first six months, with $1.7 million of operating cash outflows and cash of $2.5 million remaining. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing reliance on uncertain patent-enforcement proceeds and the need for additional capital. Long-term obligations include a secured contingent payment obligation recorded at $39.0 million (undiscounted scenarios up to $146.6 million) and unsecured contingent payment obligations of $5.8 million, both tied to future patent-related recoveries, alongside $2.3 million in convertible notes and significant ongoing IP litigation.
ParkerVision, Inc. is updating a resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of 2022 convertible notes at a fixed price of $0.13 per share.
For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue but recorded net income of $148,000, largely from a favorable $1.7 million change in the fair value of contingent payment obligations. For the first six months of 2026, it posted a net loss of $1.4 million and used $1.7 million of cash in operations.
Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against total liabilities of $48.3 million and a shareholders’ deficit of $44.6 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next year, given dependence on uncertain patent-enforcement proceeds, significant secured contingent payment obligations with fair value of $39.0 million (underlying note balance roughly $71.5 million), $5.8 million of unsecured contingent obligations, and $2.3 million of convertible notes, including $1.1 million maturing within 12 months.
ParkerVision, Inc. registered for resale up to 1,578,946 shares of common stock held by a selling stockholder, including 526,315 shares issuable upon warrant exercise. The company will not receive proceeds from share resales and would receive up to $526,315 only if the warrants are exercised for cash, for general working capital and litigation expenses.
For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, with a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, while total liabilities were $48.3 million against $3.7 million of assets, resulting in a shareholders’ deficit of $44.6 million.
The company records large secured contingent payment obligations at fair value of $39.0 million and unsecured contingent payment obligations of $5.8 million, tied to future patent‑related proceeds. Management discloses substantial doubt about its ability to continue as a going concern over the next year, citing dependence on uncertain litigation and licensing outcomes, behavior of convertible note holders, and access to additional financing.
ParkerVision, Inc. registered for resale up to 13,342,953 shares of common stock, including shares issued in prior securities purchase agreements, shares underlying 1,619,289 warrants, and shares issued for services. Selling stockholders receive sale proceeds; ParkerVision would receive up to $2,833,756 only if the warrants are exercised for cash, which it plans to use for working capital and litigation expenses.
For the quarter ended June 30, 2026, ParkerVision reported no licensing revenue and net income of $148,000, driven mainly by a favorable $1.7 million change in fair value of contingent payment obligations, while the six‑month period showed a net loss of $1.4 million. Cash was $2.5 million with working capital of $0.8 million and an accumulated deficit of $457.0 million, alongside large fair‑value liabilities for secured ($39.0 million) and unsecured ($5.8 million) contingent payment obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year.
ParkerVision, Inc. is filing a prospectus supplement covering resale of up to 5,871,584 shares of common stock by selling stockholders; the company will not receive proceeds from these sales. The supplement incorporates the June 30, 2026 Form 10-Q.
ParkerVision licenses wireless RF technologies and pursues patent-enforcement litigation as its primary business model. For the first half of 2026 it reported a net loss of $1.4 million and no licensing revenue, with cash used in operations of $1.7 million. Cash and cash equivalents were $2.5 million and working capital was about $0.8 million, against a shareholders’ deficit of $44.6 million.
The balance sheet is dominated by fair-valued contingent payment obligations tied to litigation proceeds, including $39.0 million secured and $5.8 million unsecured obligations. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year absent successful licensing, favorable note-holder behavior, cost control, and/or new financing.
ParkerVision, Inc. registered for resale by selling stockholders up to 16,809,295 shares of common stock, including shares issuable upon conversion of convertible notes and exercise of warrants. The company will not receive proceeds from these resales, but could receive up to $3.9 million in gross proceeds if Aspire and Tailwinds warrants are exercised for cash, to be used for general working capital and corporate purposes.
For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000 and a six‑month net loss of $1.4 million, with $2.5 million in cash and cash equivalents and an accumulated deficit of $457.0 million. Fair value of secured and unsecured contingent payment obligations totaled $44.8 million, and management disclosed substantial doubt about the ability to continue as a going concern given limited working capital, upcoming convertible debt maturities, and dependence on uncertain patent‑enforcement proceeds.
ParkerVision, Inc. has registered for resale by existing holders up to 18,014,164 shares of common stock, including shares issuable upon conversion of prior convertible notes, for services and upon exercise of a consulting warrant. The company will not receive proceeds from stockholder resales, but could receive up to $180,000 in cash if the consulting warrant is exercised, which would be used for general working capital and corporate purposes.
For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, but a six‑month net loss of $1.4 million and operating cash outflows of $1.7 million. Cash and cash equivalents were $2.5 million, with total assets of $3.7 million versus total liabilities of $48.3 million, resulting in a shareholders’ deficit of $44.6 million. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next year, given recurring losses, limited liquidity, and $2.3 million of convertible notes, of which $1.1 million is current, plus large secured and unsecured contingent payment obligations tied to future patent-enforcement proceeds.
ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under multiple shelf and Form S-1 registration statements. The company will not receive proceeds from these resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from share and warrant sales under the Aspire Capital agreement, which it expects to use for patent enforcement, working capital, and general corporate purposes.
For the quarter ended June 30, 2026, ParkerVision reported net income of $148,000, driven largely by a $1.7 million gain from remeasuring contingent payment obligations, while posting a six‑month net loss of $1.4 million. Cash and cash equivalents were $2.5 million, working capital was about $0.8 million, and the company reported a shareholders’ deficit of $44.6 million with an accumulated deficit of $457.0 million. Management discloses that substantial doubt exists about its ability to continue as a going concern absent successful patent licensing outcomes, favorable behavior from convertible note holders, and/or new debt or equity financing.